Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032465 | 0.96 | GNAI3 (0.45) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL19032546 | 0.95 | GNAO1 (0.47) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL20589918 | 0.95 | GNAO1 (0.47) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL19032418 | 0.93 | GNAO1 (0.47) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL20588862 | 0.93 | GNAI3 (0.47) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL20589546 | 0.93 | GNAI3 (0.47) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL19032420 | 0.92 | GNAO1 (0.45) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL19032425 | 0.91 | GNAO1 (0.47) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL20589495 | 0.88 | DNM1 (0.45) | GNAO1GNAI3GNAI1DNM1DGKA | |
| SCHEMBL5177645 | 0.88 | DNM1 (0.52) | GNAO1GNAI3GNAI1DNM1DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4036079-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ModernaTX, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3638678-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018232120-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-22 | — | — | US | disclosed |
| EP-3394030-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.